Use of simeprevir following pre-emptive pegylated interferon/ribavirin treatment for recurrent hepatitis C in living donor liver transplant recipients: A 12-week pilot study

Journal of Hepato-Biliary-Pancreatic Sciences

Volumn 22, Issue 2, 2015, Pages 144-150

  Tanaka, Tomohiro ^a   Sugawara, Yasuhiko ^b   Akamatsu, Nobuhisa ^b   Kaneko, Junichi ^b   Tamura, Sumihito ^b   Aoki, Taku ^b   Sakamoto, Yoshihiro ^b   Hasegawa, Kiyoshi ^b   Kurosaki, Masayuki ^c   Izumi, Namiki ^c   Kokudo, Norihiro ^b  

^a UNIVERSITY OF TOKYO HOSPITAL   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c MUSASHINO RED CROSS HOSPITAL   (Japan)

Author keywords

Direct acting antiviral drugs; Hepatitis C; Living donor liver transplantation; Simeprevir

Indexed keywords

BILIRUBIN; CALCINEURIN INHIBITOR; CYCLOSPORIN A; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NONSTRUCTURAL PROTEIN 3; PEGINTERFERON ALPHA2B PLUS RIBAVIRIN; SIMEPREVIR; TACROLIMUS; VIRUS RNA; ALPHA INTERFERON; ANTIVIRUS AGENT; DRUG CARRIER; MACROGOL DERIVATIVE; PEGINTERFERON ALPHA2A; RECOMBINANT PROTEIN; RIBAVIRIN;

ADD ON THERAPY; ADULT; AGED; ANEMIA; ANTIVIRAL THERAPY; ARTICLE; BILIRUBIN BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CYTOPENIA; DIARRHEA; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; FEASIBILITY STUDY; FEMALE; GRAFT INFECTION; GRAFT RECIPIENT; GRAFT REJECTION; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTIOUS COMPLICATION; KIDNEY DYSFUNCTION; KIDNEY INJURY; LIMIT OF QUANTITATION; LIVER TRANSPLANTATION; LIVING DONOR; LOW DRUG DOSE; MAINTENANCE DRUG DOSE; MALE; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PILOT STUDY; PROSPECTIVE STUDY; RECURRENCE RISK; RECURRENT INFECTION; RISK REDUCTION; STEROID THERAPY; TREATMENT RESPONSE; VIRUS MUTATION; ADVERSE EFFECTS; DRUG COMBINATION; FOLLOW UP; GENETICS; HEPACIVIRUS; HEPATITIS C, CHRONIC; RECURRENT DISEASE; TIME; TREATMENT OUTCOME; VIROLOGY;

AGED; ANTIVIRAL AGENTS; DRUG CARRIERS; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; LIVER TRANSPLANTATION; LIVING DONORS; MALE; MIDDLE AGED; PILOT PROJECTS; POLYETHYLENE GLYCOLS; PROSPECTIVE STUDIES; RECOMBINANT PROTEINS; RECURRENCE; RIBAVIRIN; RNA, VIRAL; SIMEPREVIR; TIME FACTORS; TRANSPLANT RECIPIENTS; TREATMENT OUTCOME;

EID: 84921970325     PISSN: 18686974     EISSN: 18686982     Source Type: Journal    
DOI: 10.1002/jhbp.171     Document Type: Article

References (29)

1. Forman LM, Lewis JD, Berlin JA, Feldman HI, Lucey MR,. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology. 2002; 122: 889-896.
2. Berenguer M, Prieto M, San Juan F, Rayon JM, Martinez F, Carrasco D, et-al. Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipients. Hepatology. 2002; 36: 202-210.
3. Neumann UP, Berg T, Bahra M, Puhl G, Guckelberger O, Langrehr JM, et-al. Long-term outcome of liver transplants for chronic hepatitis C: a 10-year follow-up. Transplantation. 2004; 77: 226-231.
4. Tanaka T, Selzner N, Therapondos G, Renner EL, Lilly LB,. Virological response for recurrent hepatitis C improves long-term survival in liver transplant recipients. Transpl Int. 2013; 26: 42-49.
5. Guillouche P, Feray C,. Systematic review: anti-viral therapy of recurrent hepatitis C after liver transplantation. Aliment Pharmacol Ther. 2011; 33: 163-174.
6. Berenguer M,. Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirin. J Hepatol. 2008; 49: 274-287.
7. Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB, American Association for Study of Liver D,. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology. 2011; 54: 1433-1444.
8. Pawlotsky JM,. New hepatitis C therapies: the toolbox, strategies, and challenges. Gastroenterology. 2014; 146: 1176-1192.
9. Gane EJ, Agarwal K,. Directly Acting Antivirals (DAAs) for the treatment of chronic hepatitis C virus infection in liver transplant patients: "a flood of opportunity". Am J Transplant. 2014; 14: 994-1002.
10. Tischer S, Fontana RJ,. Drug-drug interactions with oral anti-HCV agents and idiosyncratic hepatotoxicity in the liver transplant setting. J Hepatol. 2014; 60: 872-884.
11. Tamura S, Sugawara Y, Yamashiki N, Kaneko J, Kokudo N, Makuuchi M,. Pre-emptive antiviral therapy in living donor liver transplantation for hepatitis C: observation based on a single-center experience. Transpl Int. 2010; 23: 580-588.
12. Kishi Y, Sugawara Y, Akamatsu N, Kaneko J, Tamura S, Kokudo N, et-al. Splenectomy and preemptive interferon therapy for hepatitis C patients after living-donor liver transplantation. Clin Transplant. 2005; 19: 769-772.
13. Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, et-al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009; 53: 982-992.
14. Enomoto N, Sakuma I, Asahina Y, Kurosaki M, Murakami T, Yamamoto C, et-al. Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N Engl J Med. 1996; 334: 77-81.
15. Harada N, Tamura S, Sugawara Y, Togashi J, Ishizawa T, Kaneko J, et-al. Impact of donor and recipient single nucleotide polymorphisms of IL28B rs8099917 in living donor liver transplantation for hepatitis C. PLoS ONE. 2014; 9: e90462.
16. Bedossa P, Poynard T,. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology. 1996; 24: 289-293.
17. Sugawara Y, Makuuchi M, Kaneko J, Ohkubo T, Imamura H, Kawarasaki H,. Correlation between optimal tacrolimus doses and the graft weight in living donor liver transplantation. Clin Transplant. 2002; 16: 102-106.
18. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, et-al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996; 334: 693-699.
19. Powers KA, Ribeiro RM, Patel K, Pianko S, Nyberg L, Pockros P, et-al. Kinetics of hepatitis C virus reinfection after liver transplantation. Liver Transpl. 2006; 12: 207-216.
20. Garcia-Retortillo M, Forns X, Feliu A, Moitinho E, Costa J, Navasa M, et-al. Hepatitis C virus kinetics during and immediately after liver transplantation. Hepatology. 2002; 35: 680-687.
21. Lenz O, Verbinnen T, Lin TI, Vijgen L, Cummings MD, Lindberg J, et-al. In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435. Antimicrob Agents Chemother. 2010; 54: 1878-1887.
22. Kumada H, Suzuki Y, Ikeda K, Toyota J, Karino Y, Chayama K, et-al. Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection. Hepatology. 2014; 59: 2083-2091.
23. Paolucci S, Fiorina L, Mariani B, Gulminetti R, Novati S, Barbarini G, et-al. Naturally occurring resistance mutations to inhibitors of HCV NS5A region and NS5B polymerase in DAA treatment-naive patients. Virol J. 2013; 10: 355.
24. Pungpapong S, Aqel BA, Koning L, Murphy JL, Henry TM, Ryland KL, et-al. Multicenter experience using telaprevir or boceprevir with peginterferon and ribavirin to treat hepatitis C genotype 1 after liver transplantation. Liver Transpl. 2013; 19: 690-700.
25. Coilly A, Roche B, Dumortier J, Leroy V, Botta-Fridlund D, Radenne S, et-al. Safety and efficacy of protease inhibitors to treat hepatitis C after liver transplantation: a multicenter experience. J Hepatol. 2014; 60: 78-86.
26. Kwo PY, Ghabril M, Lacerda MA, Tector AJ, Fridell JA, Vianna R,. Telaprevir with peginterferon/ribavirin for retreatment of null responders with advanced fibrosis post orthotopic liver transplant. Clin Transplant. 2014; 28: 722-727.
27. Kawaoka T, Takahashi S, Tatsukawa Y, Hiramatsu A, Hiraga N, Miki D, et-al. Two patients treated with pegylated interferon/ribavirin/telaprevir triple therapy for recurrent hepatitis C after living donor liver transplantation. Hepatol Res. 2014; doi: 10.1111/hepr.12296.
28. Hayashi N, Izumi N, Kumada H, Okanoue T, Tsubouchi H, Yatsuhashi H, et-al. Simeprevir with peginterferon/ribavirin for treatment-naive hepatitis C genotype 1 patients in Japan: CONCERTO-1, a phase III Trial. J Hepatol. 2014; 61: 219-227.
29. Izumi N, Hayashi N, Kumada H, Okanoue T, Tsubouchi H, Yatsuhashi H, et-al. Once-daily simeprevir with peginterferon and ribavirin for treatment-experienced HCV genotype 1-infected patients in Japan: the CONCERTO-2 and CONCERTO-3 studies. J Gastroenterol. 2014; 49: 941-953.